Literature DB >> 31738396

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.

Ryan K Shields1,2,3, Erin K McCreary3, Rachel V Marini3, Ellen G Kline1, Chelsea E Jones1, Binghua Hao1,2, Liang Chen4, Barry N Kreiswirth4, Yohei Doi1, Cornelius J Clancy1,2,5, M Hong Nguyen1,2,3.   

Abstract

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  KPC; meropenem; porin; resistance; vaborbactam

Year:  2020        PMID： 31738396      PMCID： PMC7768741          DOI： 10.1093/cid/ciz1131

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  21 in total

1.  Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Authors:  David C Griffith; Mojgan Sabet; Ziad Tarazi; Olga Lomovskaya; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis.

Authors:  Wesley D Kufel; Ambika P Eranki; Kristopher M Paolino; Andrea Call; Christopher D Miller; Bryan T Mogle
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

3.  Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.

Authors:  Mojgan Sabet; Ziad Tarazi; Debora Rubio-Aparicio; Thomas G Nolan; Jonathan Parkinson; Olga Lomovskaya; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.

Authors:  Adrian Sousa; María Teresa Pérez-Rodríguez; Adriana Soto; Lorena Rodríguez; Antonio Pérez-Landeiro; Lucia Martínez-Lamas; Andrés Nodar; Manuel Crespo
Journal:  J Antimicrob Chemother       Date:  2018-11-01       Impact factor: 5.790

5.  Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Authors:  Helio S Sader; Mariana Castanheira; Dee Shortridge; Rodrigo E Mendes; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

8.  Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Authors:  Eric Wenzler; Mark H Gotfried; Jeffrey S Loutit; Stephanie Durso; David C Griffith; Michael N Dudley; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

9.  Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.

Authors:  Olga Lomovskaya; Dongxu Sun; Debora Rubio-Aparicio; Kirk Nelson; Ruslan Tsivkovski; David C Griffith; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

10.  Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data.

Authors:  Cornelius J Clancy; Brian A Potoski; Deanna Buehrle; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2019-07-28       Impact factor: 3.835
View more
  26 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 2.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

3.  Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.

Authors:  Ahmed Babiker; Lloyd G Clarke; Melissa Saul; Julie A Gealey; Cornelius J Clancy; M Hong Nguyen; Ryan K Shields
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

4.  Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections.

Authors:  Helen L Zhang; Leigh Cressman; Ebbing Lautenbach
Journal:  J Glob Antimicrob Resist       Date:  2021-11-12       Impact factor: 4.035

5.  Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

6.  In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.

Authors:  Abigail M Rubio; Ellen G Kline; Chelsea E Jones; Liang Chen; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy; Vaughn S Cooper; Ghady Haidar; Daria Van Tyne; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2021-05-18       Impact factor: 5.191

7.  Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients.

Authors:  M Hong Nguyen; Ryan K Shields; Liang Chen; A William Pasculle; Binghua Hao; Shaoji Cheng; Jonathan Sun; Ellen G Kline; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Clin Infect Dis       Date:  2022-02-11       Impact factor: 9.079

8.  Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.

Authors:  Sara Alosaimy; Abdalhamid M Lagnf; Taylor Morrisette; Marco R Scipione; Jing J Zhao; Sarah C J Jorgensen; Ryan Mynatt; Travis J Carlson; Jinhee Jo; Kevin W Garey; David Allen; Kailynn DeRonde; Ana D Vega; Lilian M Abbo; Veena Venugopalan; Vasilios Athans; Stephen Saw; Kimberly C Claeys; Mathew Miller; Kyle C Molina; Michael Veve; Wesley D Kufel; Lee Amaya; Christine Yost; Jessica Ortwine; Susan L Davis; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-07-14       Impact factor: 3.835

9.  In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms.

Authors:  Kirk Nelson; Debora Rubio-Aparicio; Dongxu Sun; Michael Dudley; Olga Lomovskaya
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

10.  Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3.

Authors:  Giusy Tiseo; Marco Falcone; Alessandro Leonildi; Cesira Giordano; Simona Barnini; Gabriele Arcari; Alessandra Carattoli; Francesco Menichetti
Journal:  Open Forum Infect Dis       Date:  2021-03-20       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.